SBK Successfully Holds 2025 Annual Performance Review Meeting

Recently, Chengdu Shibeikang Biomedical Technology Co., Ltd. (“SBK”) successfully held its 2025 Annual Performance Review Meeting in Chengdu. The meeting was organized by the Human Resources Department and attended by Chairman Tan Shaojun and General Manager Dr. Cen Guodong. Company leadership and department heads participated in the review, taking a comprehensive look at the past year’s achievements and outlining key priorities for the year ahead.

This meeting is designed to set a benchmark for excellence, motivate employees, foster team cohesion, and boost overall competitiveness. By recognizing outstanding achievements, it aims to elevate managers' awareness of their roles and responsibilities, emphasizing commitment and innovation in line with SBK's core values of "‘People-centered’, Driven by Change, Innovation at the Core".

During the review session, company leaders and department heads presented annual reports for their teams and individual performance. Supported by data and results, they reviewed 2025 progress across several key areas, including system upgrades, R&D innovation, production optimization, quality control, HR and administrative support, and project implementation. They also identified challenges and outlined practical plans for 2026.

Chairman Tan Shaojun and General Manager Dr. Cen Guodong then summarized SBK’s overall performance in 2025, highlighting major breakthroughs across multiple areas and important milestones in R&D. Building on these achievements, they shared forward-looking and strategic recommendations focused on project advancement, platform development, team building, strategic planning, and corporate governance, while setting higher expectations for the company’s future growth.

Looking ahead to 2026, SBK will continue to strengthen its innovation-driven approach, expand technological R&D, and steadily advance differentiated and global strategies to further enhance its presence in the biopharmaceutical industry. At the same time, the company will place greater emphasis on talent development and team building, supporting the growth of every employee. This performance review meeting marks a new starting point. Moving forward, SBK will reinforce its foundation through systemic innovation, overcome development challenges with technological breakthroughs, and pursue new milestones in pharmaceutical innovation in the year ahead.